PHARMACOLOGY SHARED RESOURCE (Core-529) ABSTRACT Overview: An important component of drug-based studies is the assessment of drug exposure in both preclinical and clinical studies. The Pharmacology Shared Resource (PharmSR) provides a mechanism by which University of Colorado Cancer Center (UCCC) investigators can plan and carry out pharmacokinetic (PK) and pharmacodynamic (PD) studies in consultation with expert investigators. Equipment: Quantitative analytical methods offered include high performance liquid chromatography (HPLC) with UV/Vis and fluorescent detection, LC tandem mass spectrometry (LC/MS/MS), and other biochemical analysis methods (e.g. ELISA, enzymatic). Institutional support led to the purchase of an AB SCIEX QTRAP? 6500 LC/MS/MS system during the last funding period, providing state of the art technology to UCCC investigators. Services: Services offered by the PharmSR include: (1) consultation on PK study design; (2) development, validation and implementation of appropriate analytical assays for drugs in biological fluids and tissues; and (3) PK and PD modeling and mathematical analysis of analytical data. PK modeling services include systems based approaches (non- compartmental modeling), compartmental modeling, Physiologically-Based PK analyses (PBPK) and population approaches. Consultation and Education: The PharmSR provides consultation to help members with limited pharmacology or PK background to design appropriate experiments and analyze PK data. Consultations provided to members roughly equates to approximately 5 letters of support being requested annually for grant submission proposing use of the PharmSR. Management: The PharmSR is located at CSU and is an institutional core jointly managed by the UCCC and CSU. CCSG funding represents 24% of the annual operating budget. The remaining support comes from the CCTSI grant (13%) and user fees (63%). PharmSR is overseen by the Associate Director of Translational Research. Use of Services: Since July 2011, 55 investigators have used the PharmSR services. Thirty-six percent (20) were UCCC members representing four of the six UCCC programs and generating 20 peer-reviewed publications. Future Directions: The Pharm SR is currently establishing multiplex assays to directly quantitate panels of ATP-binding cassette (ABC) transporter proteins and drug metabolizing enzymes (P450s) from in vitro, preclinical and patient specimens. The goal is for the PharmSR to offer these focused proteomic assays to quantitate proteins relevant to drug development and mechanism of action.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ryan, Weston Kenneth; Fernandez, Josiah; Peterson, Mikayla Katherine et al. (2018) Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase. Cell Death Differ :
Monks, Jenifer; Orlicky, David J; Stefanski, Adrianne L et al. (2018) Maternal obesity during lactation may protect offspring from high fat diet-induced metabolic dysfunction. Nutr Diabetes 8:18
Garcia, Tamara B; Fosmire, Susan P; Porter, Christopher C (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30-33
Wahdan-Alaswad, R S; Edgerton, S M; Salem, H S et al. (2018) Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res 4:
Oweida, Ayman; Phan, Andy; Vancourt, Benjamin et al. (2018) Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 28:739-747
Gadalla, Shahinaz M; Wang, Tao; Loftus, David et al. (2018) No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 53:383-391

Showing the most recent 10 out of 1634 publications